Loading...

OKYO Pharma

LSE:OKYO
Snowflake Description

Adequate balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
OKYO
LSE
£10M
Market Cap
  1. Home
  2. GB
  3. Pharmaceuticals & Biotech
Company description

OKYO Pharma Limited operates as a life sciences and biotechnology company in the United Kingdom. The last earnings update was 172 days ago. More info.


Add to Portfolio Compare Print
  • OKYO Pharma has significant price volatility in the past 3 months.
OKYO Share Price and Events
7 Day Returns
0%
LSE:OKYO
0.7%
GB Biotechs
1.5%
GB Market
1 Year Returns
-
LSE:OKYO
25.5%
GB Biotechs
-6.3%
GB Market
OKYO Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
OKYO Pharma (OKYO) 0% 48.1% 50.9% - -23.8% -68.6%
GB Biotechs 0.7% 4.2% 4.1% 25.5% 11.8% 53.8%
GB Market 1.5% -2.1% 1.8% -6.3% 15.4% 2%
1 Year Return vs Industry and Market
  • No trading data on OKYO.
  • No trading data on OKYO.
Price Volatility
OKYO
Industry
5yr Volatility vs Market

OKYO Value

 Is OKYO Pharma undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for OKYO Pharma. This is due to cash flow or dividend data being unavailable. The share price is £0.02.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for OKYO Pharma's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are OKYO Pharma's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
LSE:OKYO PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-09-30) in GBP £-0.08
LSE:OKYO Share Price ** LSE (2019-05-21) in GBP £0.02
United Kingdom of Great Britain and Northern Ireland Biotechs Industry PE Ratio Median Figure of 5 Publicly-Listed Biotechs Companies 35.77x
United Kingdom of Great Britain and Northern Ireland Market PE Ratio Median Figure of 789 Publicly-Listed Companies 16.22x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of OKYO Pharma.

LSE:OKYO PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= LSE:OKYO Share Price ÷ EPS (both in GBP)

= 0.02 ÷ -0.08

-0.26x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • OKYO Pharma is loss making, we can't compare its value to the GB Biotechs industry average.
  • OKYO Pharma is loss making, we can't compare the value of its earnings to the United Kingdom of Great Britain and Northern Ireland market.
Price based on expected Growth
Does OKYO Pharma's expected growth come at a high price?
Raw Data
LSE:OKYO PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.26x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
United Kingdom of Great Britain and Northern Ireland Biotechs Industry PEG Ratio Median Figure of 5 Publicly-Listed Biotechs Companies 1.52x
United Kingdom of Great Britain and Northern Ireland Market PEG Ratio Median Figure of 575 Publicly-Listed Companies 1.5x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for OKYO Pharma, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on OKYO Pharma's assets?
Raw Data
LSE:OKYO PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-09-30) in GBP £0.00
LSE:OKYO Share Price * LSE (2019-05-21) in GBP £0.02
United Kingdom of Great Britain and Northern Ireland Biotechs Industry PB Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 2.7x
United Kingdom of Great Britain and Northern Ireland Market PB Ratio Median Figure of 1,368 Publicly-Listed Companies 1.5x
LSE:OKYO PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= LSE:OKYO Share Price ÷ Book Value per Share (both in GBP)

= 0.02 ÷ 0.00

9.59x

* Primary Listing of OKYO Pharma.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • OKYO Pharma is overvalued based on assets compared to the GB Biotechs industry average.
X
Value checks
We assess OKYO Pharma's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. OKYO Pharma has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

OKYO Future Performance

 How is OKYO Pharma expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as OKYO Pharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
12.4%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is OKYO Pharma expected to grow at an attractive rate?
  • Unable to compare OKYO Pharma's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare OKYO Pharma's earnings growth to the United Kingdom of Great Britain and Northern Ireland market average as no estimate data is available.
  • Unable to compare OKYO Pharma's revenue growth to the United Kingdom of Great Britain and Northern Ireland market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
LSE:OKYO Future Growth Rates Data Sources
Data Point Source Value (per year)
United Kingdom of Great Britain and Northern Ireland Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 12.4%
United Kingdom of Great Britain and Northern Ireland Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 4.2%
United Kingdom of Great Britain and Northern Ireland Market Earnings Growth Rate Market Cap Weighted Average 11%
United Kingdom of Great Britain and Northern Ireland Market Revenue Growth Rate Market Cap Weighted Average 5%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
LSE:OKYO Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (7 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in GBP Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
LSE:OKYO Past Financials Data
Date (Data in GBP Millions) Revenue Cash Flow Net Income *
2018-09-30 -2 -35
2018-06-30 -1 -44
2018-03-31 -1 -53
2017-12-31 -1 -36
2017-09-30 -1 -19
2017-06-30 -1 -10
2017-03-31 -1 0
2016-12-31 0 0
2016-09-30 0 0
2016-06-30 0 -1
2016-03-31 0 -1

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if OKYO Pharma is high growth as no earnings estimate data is available.
  • Unable to determine if OKYO Pharma is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
LSE:OKYO Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (7 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from OKYO Pharma Company Filings, last reported 7 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

LSE:OKYO Past Financials Data
Date (Data in GBP Millions) EPS *
2018-09-30 -0.08
2018-06-30 -0.11
2018-03-31 -0.14
2017-12-31 -0.10
2017-09-30 -0.05
2017-06-30 -0.03
2017-03-31 0.00
2016-12-31 0.00
2016-09-30 0.00
2016-06-30 0.00
2016-03-31 0.00

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if OKYO Pharma will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine OKYO Pharma's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. OKYO Pharma's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. OKYO Pharma's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess OKYO Pharma's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
OKYO Pharma has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

OKYO Past Performance

  How has OKYO Pharma performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare OKYO Pharma's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • OKYO Pharma does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare OKYO Pharma's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare OKYO Pharma's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
OKYO Pharma's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from OKYO Pharma Company Filings, last reported 7 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

LSE:OKYO Past Revenue, Cash Flow and Net Income Data
Date (Data in GBP Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-09-30 -35.08 1.14
2018-06-30 -44.12 0.78
2018-03-31 -53.15 0.41
2017-12-31 -36.25 0.32
2017-09-30 -19.35 0.24
2017-06-30 -9.77 0.26
2017-03-31 -0.19 0.29
2016-12-31 -0.30 0.41
2016-09-30 -0.41 0.53
2016-06-30 -0.56 0.63
2016-03-31 -0.70 0.73
2015-09-30 -0.73 0.91
2015-06-30 -0.87 1.05
2015-03-31 -1.01 1.18
2014-12-31 -4.13 1.87
2014-09-30 -2.68 2.52
2014-06-30 -5.52 2.64
2014-03-31 -8.37 2.77
2013-12-31 -8.12 2.61
2013-09-30 -7.87 2.45
2013-06-30 -5.47 2.76
2013-03-31 -3.06 3.07
2012-12-31 -3.26 3.11
2012-09-30 -3.46 3.15
2012-06-30 -3.23 3.22

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if OKYO Pharma has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if OKYO Pharma has efficiently used its assets last year compared to the GB Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if OKYO Pharma improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess OKYO Pharma's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
OKYO Pharma has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

OKYO Health

 How is OKYO Pharma's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up OKYO Pharma's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • OKYO Pharma is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • OKYO Pharma has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of OKYO Pharma's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • OKYO Pharma has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from OKYO Pharma Company Filings, last reported 7 months ago.

LSE:OKYO Past Debt and Equity Data
Date (Data in GBP Millions) Total Equity Total Debt Cash & Short Term Investments
2018-09-30 1.09 0.00 1.24
2018-06-30 1.09 0.00 1.24
2018-03-31 1.92 0.00 2.01
2017-12-31 1.92 0.00 2.01
2017-09-30 2.64 0.00 2.67
2017-06-30 2.64 0.00 2.67
2017-03-31 54.89 0.00 16.52
2016-12-31 54.89 0.00 16.52
2016-09-30 22.22 0.00 3.44
2016-06-30 22.22 0.00 3.44
2016-03-31 22.27 0.00 3.57
2015-09-30 22.52 0.00 3.94
2015-06-30 22.52 0.00 3.94
2015-03-31 22.89 0.00 4.37
2014-12-31 22.89 0.00 4.37
2014-09-30 27.56 0.00 5.35
2014-06-30 27.56 0.00 5.35
2014-03-31 28.21 0.00 7.10
2013-12-31 28.21 0.00 7.10
2013-09-30 23.38 0.00 3.51
2013-06-30 23.38 0.00 3.51
2013-03-31 29.63 0.00 9.44
2012-12-31 29.63 0.00 9.44
2012-09-30 30.29 0.00 12.94
2012-06-30 30.29 0.00 12.94
  • OKYO Pharma has no debt.
  • OKYO Pharma has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • OKYO Pharma has less than a year of cash runway based on current free cash flow.
  • OKYO Pharma has less than a year of cash runway if free cash flow continues to grow at historical rates of 48.2% each year.
X
Financial health checks
We assess OKYO Pharma's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. OKYO Pharma has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

OKYO Dividends

 What is OKYO Pharma's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from OKYO Pharma dividends.
If you bought £2,000 of OKYO Pharma shares you are expected to receive £0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate OKYO Pharma's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate OKYO Pharma's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
LSE:OKYO Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.8%
United Kingdom of Great Britain and Northern Ireland Market Average Dividend Yield Market Cap Weighted Average of 705 Stocks 4.3%
United Kingdom of Great Britain and Northern Ireland Minimum Threshold Dividend Yield 10th Percentile 1%
United Kingdom of Great Britain and Northern Ireland Bottom 25% Dividend Yield 25th Percentile 2%
United Kingdom of Great Britain and Northern Ireland Top 25% Dividend Yield 75th Percentile 5.3%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as OKYO Pharma has not reported any payouts.
  • Unable to verify if OKYO Pharma's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of OKYO Pharma's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as OKYO Pharma has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess OKYO Pharma's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can OKYO Pharma afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. OKYO Pharma has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

OKYO Management

 What is the CEO of OKYO Pharma's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
  • OKYO Pharma has no CEO, or we have no data on them.
Management Team

Willy Simon

TITLE
Acting Chairman
AGE
67

Mike Beck

TITLE

Tiziano Lazzaretti

TITLE
Chief Financial Officer
AGE
59
TENURE
1.3 yrs

Raj Patil

TITLE
Senior Director of Research & Development
TENURE
0.7 yrs
Board of Directors Tenure

Average tenure and age of the OKYO Pharma board of directors in years:

1.5
Average Tenure
60
Average Age
  • The average tenure for the OKYO Pharma board of directors is less than 3 years, this suggests a new board.
Board of Directors

Willy Simon

TITLE
Acting Chairman
AGE
67
TENURE
1.5 yrs

Leopoldo Zambeletti

TITLE
Non-Executive Director
AGE
50
TENURE
1.2 yrs

Shailu Shailubhai

TITLE
Non-Executive Director
AGE
60
TENURE
1.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (£) Value (£)
X
Management checks
We assess OKYO Pharma's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. OKYO Pharma has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

OKYO News

Simply Wall St News

OKYO Company Info

Description

OKYO Pharma Limited operates as a life sciences and biotechnology company in the United Kingdom. Its development program includes Chemerin for the treatment of ocular inflammation, dry eye disease, and ocular neuropathic pain; and BAM-8, a non-opiod analgesic. OKYO Pharma Limited is based in St Peter Port, Guernsey.

Details
Name: OKYO Pharma Limited
OKYO
Exchange: LSE
Founded:
£10,482,165
524,108,283
Website: http://www.okyopharma.com
Address: OKYO Pharma Limited
Martello Court,
Admiral Park,
St Peter Port,
GY1 3HB,
Guernsey
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
LSE OKYO Ordinary Shares London Stock Exchange GB GBP 01. Jul 2008
Number of employees
Current staff
Staff numbers
0
OKYO Pharma employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/21 21:33
End of day share price update: 2019/05/21 00:00
Last earnings filing: 2018/11/30
Last earnings reported: 2018/09/30
Last annual earnings reported: 2018/03/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.